Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
PARIS and BOSTON, Nov. 03, 2016 -- Neovacs (Alternext Paris:ALNEV) a leader in active immunotherapy for the treatment of autoimmune diseases, today announced its participation at the Jefferies 2016 London Healthcare Conference taking place November 16-17 at the Waldorf Hilton in London, UK.
This Conference is the largest healthcare meeting in Europe dedicated to companies from around the world from the biotechnology, pharmaceutical, generic, consumer health, medical technology and Healthcare Service sectors. Last year, the Jefferies conference hosted over 300 participating companies, 1,200 attendees and 3,700 business-to-business and investor meetings.
The two-day event will include concurrent tracks of company presentations, thematic panel discussions, and 1x1/small-group meetings. This global gathering of leading healthcare executives and institutional, private equity and venture capital investors will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare.
About Neovacs
Listed on Alternext Paris since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr
Contacts NEOVACS – Corporate Communication & Investor Relations Charlène Masson +33 (0)1 53 10 93 14 [email protected] Investor Relations / Financial Communications Germany – MC Services Raimund Gabriel +49-89-21-02-28-30 [email protected] Press / U.S. Inquiries – The Ruth Group Lee Roth / Joseph Green +1-646-536-7012 / 7013 [email protected] / [email protected]
